Literature DB >> 3806200

Long-term intrathecal baclofen infusion for treatment of spasticity.

R D Penn, J S Kroin.   

Abstract

Seven patients with spasticity of spinal cord origin have been maintained for up to 2 years with continuous spinal intrathecal infusion of baclofen. Prior to treatment, all of the patients had severe rigidity in their lower limbs and most had frequent and extensive spontaneous spasms, all of which greatly interfered with their activities of daily living. Oral antispasmodic medications were ineffective or caused central side effects. The patients underwent implantation of a programmable drug pump connected to a lumbar subarachnoid catheter. Within days of beginning continuous intrathecal baclofen infusion, the muscle tone was reduced to normal levels and spasms were eliminated. Over the ensuing months, muscle tone remained normal, but short-duration spasms could be induced by some activities. The greatest benefits to the patients were improvement in activities of daily living and better sleep due to reduced spasms. The baclofen doses were increased over the first few months but then were stabilized or only increased slightly, with the maximum dose being 650 micrograms/day. The most serious complications were two drug overdoses which took several days to clear up and were due to malfunctions of an earlier pump model. Baclofen clearance from the cerebrospinal fluid occurs with a half-life of 5 hours. The most serious concern in maintaining patients indefinitely on intrathecal baclofen is whether drug tolerance will eventually occur.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3806200     DOI: 10.3171/jns.1987.66.2.0181

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  17 in total

Review 1.  Intrathecal drug administration. Present use and future trends.

Authors:  J S Kroin
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

2.  Intrathecal baclofen for treatment of spasticity.

Authors:  J Vanneste; P Augustijn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-08       Impact factor: 10.154

3.  CSF baclofen levels after intrathecal administration in severe spasticity.

Authors:  B Sallerin-Caute; Y Lazorthes; B Monsarrat; J Cros; R Bastide
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 4.  A systematic review of pharmacologic treatments of pain after spinal cord injury.

Authors:  Robert W Teasell; Swati Mehta; Jo-Anne L Aubut; Brianne Foulon; Dalton L Wolfe; Jane T C Hsieh; Andrea F Townson; Christine Short
Journal:  Arch Phys Med Rehabil       Date:  2010-05       Impact factor: 3.966

5.  Treatment of severe tetanus by intrathecal infusion of baclofen.

Authors:  A Pellanda; D Caldiroli; G M Vaghi; S Bonelli
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

6.  [Myoclonus resulting from high-dose epidural and intravenous morphine infusion].

Authors:  L Radbruch; D Zech; S Grond
Journal:  Med Klin (Munich)       Date:  1997-05-15

7.  Long term effect (more than five years) of intrathecal baclofen on impairment, disability, and quality of life in patients with severe spasticity of spinal origin.

Authors:  A Zahavi; J H B Geertzen; B Middel; M Staal; J S Rietman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-11       Impact factor: 10.154

8.  Intraspinal baclofen in the treatment of severe spasticity and spasms.

Authors:  J Sahuquillo; T Muxi; M Noguer; R Jodar; C Closa; E Rubio; L Garcia-Fernandez; J M Guitart
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

9.  Influence of baclofen on laryngeal and spinal motor drive during cough in the anesthetized cat.

Authors:  Daniel Castillo; Teresa Pitts
Journal:  Laryngoscope       Date:  2013-05-13       Impact factor: 3.325

10.  Evidence that gamma-aminobutyric acid is part of the neural circuit mediating estradiol negative feedback in anestrous ewes.

Authors:  Adrienne L Bogusz; Steven L Hardy; Michael N Lehman; John M Connors; Stanley M Hileman; Joanna H Sliwowska; Heather J Billings; Christina J McManus; Miroslav Valent; Sushma R Singh; Casey C Nestor; Lique M Coolen; Robert L Goodman
Journal:  Endocrinology       Date:  2008-03-06       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.